Gilead (GILD) Announced Interim Phase 2 Data on Hepatitis Drugs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Notable ETF Movers of the Day 11/12: (IBB) Higher; (XLU) (ITB) Lower
November 12, 2012 12:58 PM ESTGainers:
iShares Nasdaq Biotechnology (Nasdaq: IBB) gained 2 percent to 132.57. The move is tied to shares of Gilead Sciences (Nasdaq: GILD) which gained 12 percent on positive results for its drug combo 7977/5885 for treatment of hepatitis C. Shares of... More
Deutsche Bank Maintains Buy on Gilead Sciences (GILD) after Strong Hepatitis C Combo Data
November 12, 2012 8:39 AM ESTDeutsche Bank reiterated its Buy rating and $75 price target on Gilead Sciences (NASDAQ: GILD) following positive data from the '7977/'5885 combo in treatment-naïve genotype 1 Hepatitis C patients, showing 100 percent (n=25/25) remained HCV RNA undetectable four weeks after completing therapy (SVR4).
Commenting on... More
